Expertos Invitados





ANTICOAGULACION EN LA HIPERTENSION PULMONAR

(especial para SIIC © Derechos reservados)
Se presenta una revisión de expertos, con una breve introducción general acerca de la hipertensión pulmonar con posterior énfasis en la anticoagulación.
Autor:
Cecilia Perel
Columnista Experta de SIIC

Institución:
Hospital Bernardino Rivadavia

Artículos publicados por Cecilia Perel
Recepción del artículo
3 de Marzo, 2011 		Aprobación
2 de Febrero, 2012
Primera edición
2 de Octubre, 2012 		Segunda edición, ampliada y corregida
7 de Junio, 2021

ANTICOAGULACION EN LA HIPERTENSION PULMONAR


Artículo completo
(castellano)
Extensión:  +/-5.73 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

Anticoagulation in Pulmonary Arterial Hypertension

Clasificación en siicsalud
Artículos originales > Expertos de Iberoamérica >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Cardiología, Neumonología
Relacionadas: Anatomía Patológica, Cirugía, Cuidados Intensivos, Diagnóstico por Imágenes, Diagnóstico por Laboratorio, Epidemiología, Farmacología, Geriatría, Hematología, Medicina Farmacéutica



Comprar este artículo
Extensión: 5.73 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Enviar correspondencia a:
Cecilia Perel, Hospital Bernardino Rivadavia, C1425ASQ, Avenida Gral. Las Heras 2670, Buenos Aires, Argentina
Bibliografía del artículo
1. Badesch D, Abman S, Simonneau, G, Rubin, L, McLaughlin, V. Medical Therapy for Pulmonary Arterial Hypertension. Updated ACCP Evidence-Based Clinical Practice Guidelines. CHEST 131:1917–1928, 2007.
2. Rubin LJ. Diagnosis and Management of Pulmonary Arterial Hypertension: ACCP Evidence-based Clinical Practice Guidelines. Chest 126:7S–10S, 2004.
3. Rubin LJ. Diagnosis and Management of Pulmonary Arterial Hypertension: ACCP Evidence-based Clinical Practice Guidelines. Chest 126:4S–6S, 2004.
4. McCrory DC, Lewis SL. Methodology and Grading for Pulmonary Hypertension Evidence Review and Guideline Development. Chest 126:35S–62S, 2004.
5. McGoon M, Gutterman D, Steen V. Screening, Early Detection, and Diagnosis of Pulmonary Arterial Hypertension: ACCP Evidence-based Clinical Practice Guidelines. Chest 126:14S–34S, 2004.
6. Doyle RL, McCrory D, Channick RN. Surgical Treatments/Interventions for Pulmonary Arterial Hypertension: ACCP Evidence-based Clinical Practice Guidelines. Chest 126:63S–71S, 2004.
7. Barst RJ, Rubin LJ, Long WA, et al. A Comparison of Continuous Intravenous Epoprostenol (prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension: the Primary Pulmonary Hypertension Study Group. N Engl J Med 334:296–302, 1996.
8. Welsh CH, Hassell KL, Badesch DB,.Coagulation and Fibrinolytic Profiles in Patients with Severe Pulmonary Hypertension. Chest 110:710–717, 1996.
9. Boyer-Neumann C, Brenot F, Wolf M. Continuous Infusion of Prostacyclin Decreases Plasma Levels of t-PA and PAI-1 in Primary Pulmonary Hypertension. Thromb Haemost 73:735–736, 1995.
10. Herve P, Humbert M, Sitbon O.Pathobiology of Pulmonary Hypertension: the Role of Platelets and Thrombosis. Clin Chest Med 22:451–458, 2001.
11. Christman BW, McPherson CD,Newman JH. An Imbalance Between the Excretion of Thromboxane and Prostacyclin Metabolites in Pulmonary Hypertension. N Engl J Med 327:70–75, 1992.
12. Giaid A, Saleh D. Reduced Expression Of Endothelial Nitric Oxide Synthase in the Lungs of Patients with Pulmonary Hypertension. N Engl J Med 333:214–221, 1995.
13. Lopes AA, Maeda NY, Aiello VD. Abnormal Multimeric and Oligomeric Composition is Associated with Enhanced Endothelial Expression of Von Willebrand Factor in Pulmonary Hypertension. Chest 104:1455–1460, 1993.
14. Fanburg BL, Lee SL. A New Role for an Old Molecule: Serotonin as a Mitogen. Am J Physiol 272:L795–L806, 1997.
15. Herve P, Drouet L, Dosquet C. Primary Pulmonary Hypertension in a Patient with a Familial Platelet Storage Pool Disease: Role of Serotonin. Am J Med 89:117–120, 1990.
16. Fuster V, Steele PM, Edwards WD. Primary Pulmonary hypertension: Natural History and the Importance of Thrombosis. Circulation 70:580–587, 1984.
17. Kawut SM, Horn EM, Berekashvili KK. New Predictors of Outcome in Idiopathic Pulmonary Arterial Hypertension. Am J Cardiol 95:199–203, 2005.
18. Rich S, Kaufmann E, Levy PS. The Effect of High Doses of Calcium-channel Blockers on Survival in Primary Pulmonary Hypertension. N Engl J Med 327:76–81, 1992.
19. Badesch DB, Abman SH, Ahearn GS,. Medical Therapy for Pulmonary Arterial Hypertension: ACCP Evidence-based Clinical Practice Guidelines. Chest 126 (1 Suppl):35S–62S, 2004.
20. Christman BW, McPherson CD, Newman JH. An Imbalance Between the Excretion of Thromboxane and Prostacyclin Metabolites in Pulmonary Hypertension. N Engl J Med 327:70–75, 1992.
21. Giaid A, Saleh D. Reduced Expression of Endothelial Nitric Oxide Synthase in the Lungs of Patients with Pulmonary Hypertension. N Engl J Med 333:214–221, 1995.
22. Merkow L, ,Kleinerman J. An Electron Microscopic Study of Pulmonary Vasculitis Induced by Monocrotaline. Lab Invest 15:547–564, 1966.
23. Kanai Y, Hori S, Tanaka T.Role of 5-hydroxytryptamine in the Progression of Monocrotaline Induced Pulmonary Hypertension in rats. Cardiovasc Res 27:1619–1623, 1993.
24. Hill A. The Environment and Disease: Association or Causation? Proc R Soc Med 58:295–300, 1965.
25. Morse JH, Barst RJ, Fotino M. Primary Pulmonary Hypertension, Tissue Plasminogen Activator Antibodies, and HLA-DQ7. Am J Respir Crit Care Med 155:274–278, 1997.
26. Kawut SM, Horn EM, Berekashvili KK. New Predictors of Outcome in Idiopathic Pulmonary Arterial Hypertension. Am J Cardiol 95:199–203, 2005.
27. Badesch DB, Abman SH, Ahearn GS. Medical Therapy for Pulmonary Arterial Hypertension: ACCP Evidence-based Clinical Practice Guidelines. Chest 126 (1 Suppl):35S–62S, 2004.
28. Luchini A, Sessoms SL. Gastrointestinal Hemorrhage in Patients with Systemic Sclerosis and CREST Syndrome. Am J Gastroenterol 93:1453–1456, 1998.
29. Johnson SR, Granton JT, Mehta S. Thrombotic Arteriopathy and Anticoagulation in Pulmonary Hypertension. Chest 130; 545-552, 2006.
30. Johnson SR, Mehta S, Granton JT. Anticoagulation in Pulmonary Arterial Hypertension: a Qualitative Systematic. Review Eur Respir J 28: 999–1004, 2006.
31. DiMarco JP, Flaker G, Waldo AL. Factors Affecting Bleeding Risk During Anticoagulant Therapy in Patients with Atrial Fibrillation: Observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 149: 650–656, 2005.
32. Beyth RJ, Quinn LM, Landefeld CS. Prospective Evaluation of an Index for Predicting the risk of Major Bleeding in Outpatients Treated with Warfarin. Am J Med 105: 91–99, 1998.
33. Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH. The Risk for and Severity of Bleeding Complications in Elderly Patients Treated with Warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med 124: 970–979, 1996.
34. McMahan DA, Smith DM, Carey MA, Zhou XH. Risk of Major Hemorrhage for Outpatients Treated with Warfarin. J Gen Intern Med 13: 311–316, 1998.
35. O’Reilly RA, Motley CH. Racemic Warfarin and Trimethoprim–sulfamethoxazole Interaction in Humans. Ann Intern Med 91: 34–36, 1979.
36. O’Reilly RA. The Stereoselective Interaction of Warfarin and Metronidazole in Man. N Engl J Med 295: 354–357, 1976.
37. Weibert RT, Lorentz SM, Townsend RJ, Cook CE, Klauber MR, Jagger PI. Effect of Erythromycin in Patients Receiving long-term Warfarin Therapy. Clin Pharm 8: 210–214, 1989.
38. Heimark LD, Wienkers L, Kunze K, et al. The Mechanism of the Interaction between Amiodarone and Warfarin in Humans. Clin Pharmacol Ther 51: 398–407, 1992.
39. Almog S, Shafran N, Halkin H. Mechanism of Warfarin Potentiation by Amiodarone: Dose – and Concentration – Dependent Inhibition of Warfarin Elimination. Eur J Clin Pharmacol 28: 257–261, 1985.
40. O’Reilly RA, Trager WF, Rettie AE, Goulart DA. Interaction of Amiodarone with Racemic Warfarin and its Separated Enantiomorphs in Humans. Clin Pharmacol Ther 42: 290–294, 1987.
41. Murphey LM, Hood EH. Bosentan and Warfarin Interaction. Ann Pharmacother 37: 1028–1031, 2007.
42. Widlitz AC, Barst RJ, Horn EM. Sitaxsentan: a Novel Endothelin-A Receptor Antagonist for Pulmonary Arterial Hypertension. Expert Rev Cardiovasc Ther 3: 985–991, 2005.
43. Ogawa A, Matsubara H, Fujio H. Risk of Alveolar Hemorrhage in Patients with Primary Pulmonary Hypertension – Anticoagulation and Epoprostenol Therapy. Circ J 69: 216–220, 2005.
44. S Ulricha, M Fischlera, R Speicha. Update on Therapies for Pulmonary Hypertension. Swiss Med Wkly 137:73–82, 2007.
45. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327:76–81, 1992.
46. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111:3105–11, 2005.
47. Frank H, Mlczoch J, Huber K, et al. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest 112:714 –21, 1997.
48. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association. J. Am. Coll. Cardiol 53: 1573-1619, 2009.
Título español
 Palabras clave
 Bibliografía
 Artículo completo
(exclusivo a suscriptores)
 Autoevaluación
  Tema principal en SIIC Data Bases
 Especialidades

 English title
  Abstract
 Key words
Full text
(exclusivo a suscriptores)

Autor 
Artículos
Correspondencia
Patrocinio y reconocimiento
Imprimir esta página
 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618
Inicio/Home

Copyright siicsalud © 1997-2024 ISSN siicsalud: 1667-9008